MED LIFE S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.115 RON | +0.37% |
|
+2.88% | +3.39% |
| Apr. 03 | Med Life S.A. (BVB:M) acquired an unknown majority stake in Personal Genetics Srl. | CI |
| Feb. 29 | Med Life S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 593.5 | 745.3 | 1,473 | 3,143 | 2,223 | 2,165 | 2,165 | - |
| Enterprise Value (EV) 1 | 936.7 | 1,259 | 2,065 | 3,739 | 3,320 | 3,148 | 2,165 | 2,165 |
| P/E ratio | 44.4 x | 44.1 x | 27.2 x | - | - | - | 103 x | 68.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.75 x | 0.77 x | 1.37 x | 2.2 x | 1.23 x | 0.95 x | 0.87 x | 0.78 x |
| EV / Revenue | 1.18 x | 1.3 x | 1.92 x | 2.61 x | 1.84 x | 1.42 x | 0.87 x | 0.78 x |
| EV / EBITDA | 9.82 x | 8.41 x | 9.2 x | 12.1 x | 13.1 x | 11 x | 6.78 x | 6.13 x |
| EV / FCF | 611,390,825 x | 20,990,805 x | 45,460,711 x | 29,481,005 x | -11,777,771 x | - | 8,430,380 x | 9,651,902 x |
| FCF Yield | 0% | 0% | 0% | 0% | -0% | - | 0% | 0% |
| Price to Book | 3.73 x | 4.02 x | 6.16 x | 9.39 x | 5.38 x | 4.25 x | 4.2 x | 4 x |
| Nbr of stocks (in thousands) | 531,482 | 526,105 | 526,105 | 526,105 | 526,105 | 526,105 | 526,105 | - |
| Reference price 2 | 1.117 | 1.417 | 2.800 | 5.975 | 4.225 | 4.115 | 4.115 | 4.115 |
| Announcement Date | 2/18/19 | 2/21/20 | 2/26/21 | 2/25/22 | 2/24/23 | 2/29/24 | - | - |
1RON in Million2RON
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 794.6 | 967.4 | 1,078 | 1,432 | 1,806 | 2,210 | 2,491 | 2,779 |
| EBITDA 1 | 95.38 | 149.7 | 224.6 | 308.4 | 254.2 | 287.1 | 319.2 | 352.9 |
| EBIT 1 | 38.39 | 56.37 | 119.8 | 187.2 | 102.7 | 91.52 | 155.9 | 181.2 |
| Operating Margin | 4.83% | 5.83% | 11.11% | 13.07% | 5.69% | 4.14% | 6.26% | 6.52% |
| Earnings before Tax (EBT) | 23.83 | 29.02 | 78.81 | 141.1 | - | - | 26.8 | 35.89 |
| Net income | 13.37 | 17.09 | 54.62 | - | - | - | 22.51 | 30.15 |
| Net margin | 1.68% | 1.77% | 5.07% | - | - | - | 0.9% | 1.08% |
| EPS | 0.0252 | 0.0322 | 0.1028 | - | - | - | 0.0400 | 0.0600 |
| Free Cash Flow | 1.532 | 59.96 | 45.43 | 126.8 | -281.9 | - | 256.8 | 224.3 |
| FCF margin | 0.19% | 6.2% | 4.21% | 8.86% | -15.61% | - | 10.31% | 8.07% |
| FCF Conversion (EBITDA) | 1.61% | 40.06% | 20.23% | 41.14% | - | - | 80.45% | 63.55% |
| FCF Conversion (Net income) | 11.46% | 350.86% | 83.18% | - | - | - | 1,140.83% | 743.95% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/19 | 2/21/20 | 2/26/21 | 2/25/22 | 2/24/23 | 2/29/24 | - | - |
1RON in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2021 Q2 | 2021 S1 | 2021 Q3 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 468.3 | 339.5 | 677.3 | 368.9 | 420.9 | 439.5 | 860.4 | 469.2 |
| EBITDA 1 | 73.96 | 76.19 | 155.9 | 69.42 | - | 63.5 | 135.7 | 62.39 |
| EBIT 1 | 28.12 | 49.52 | 103.1 | 42.95 | - | 28.32 | 69.18 | 26.26 |
| Operating Margin | 6% | 14.58% | 15.23% | 11.64% | - | 6.44% | 8.04% | 5.6% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | 27.29 | - | - | - |
| Net margin | - | - | - | - | 6.48% | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/13/19 | 8/26/21 | 8/26/21 | 11/12/21 | 5/13/22 | 8/26/22 | 8/26/22 | 11/11/22 |
1RON in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 343 | 513 | 592 | 596 | 1,097 | 1,054 | - | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.599 x | 3.429 x | 2.637 x | 1.933 x | 4.317 x | 3.672 x | - | - |
| Free Cash Flow | 1.53 | 60 | 45.4 | 127 | -282 | - | 257 | 224 |
| ROE (net income / shareholders' equity) | 8.36% | 15.7% | 25.6% | 42.2% | 11.1% | -1.2% | 4.5% | 5.7% |
| ROA (Net income/ Total Assets) | 1.92% | 3.07% | 4.88% | - | - | - | - | - |
| Assets | 697.9 | 557.1 | 1,120 | - | - | - | - | - |
| Book Value Per Share 2 | 0.3000 | 0.3500 | 0.4500 | 0.6400 | 0.7800 | 0.9400 | 0.9800 | 1.030 |
| Cash Flow per Share | 0.1000 | 0.2100 | 0.2400 | 0.4300 | - | - | - | - |
| Capex | 49.9 | 50.7 | 80.3 | 87.2 | 160 | - | 75 | 75 |
| Capex / Sales | 6.28% | 5.24% | 7.45% | 6.09% | 8.84% | - | 3.01% | 2.7% |
| Announcement Date | 2/18/19 | 2/21/20 | 2/26/21 | 2/25/22 | 2/24/23 | 2/29/24 | - | - |
1RON in Million2RON
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4.115
RON
Average target price
4.983
RON
Spread / Average Target
+21.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.39% | 464M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +11.62% | 29.59B | |
| -12.71% | 16.73B | |
| -2.35% | 16.36B | |
| -2.63% | 14.92B | |
| -31.58% | 11.77B | |
| -0.05% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- M Stock
- Financials Med Life S.A.
